These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9280118)

  • 41. Influences of immunosuppressive agents, FK506 and cyclosporin on systemic Candida albicans infection in mice.
    Ito E; Tanaka Y
    Mycopathologia; 1997; 138(2):57-64. PubMed ID: 9433807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The immunological effects of perftoran].
    Pluzhnikov NN; Lobzin IuV; Kovelenov AIu; Zhelezkova EV; Gusev DA
    Eksp Klin Farmakol; 1998; 61(5):34-6. PubMed ID: 9854631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycyrrhizin improves the resistance of MAIDS mice to opportunistic infection of Candida albicans through the modulation of MAIDS-associated type 2 T cell responses.
    Utsunomiya T; Kobayashi M; Ito M; Pollard RB; Suzuki F
    Clin Immunol; 2000 May; 95(2):145-55. PubMed ID: 10779408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Host resistance to Candida albicans infection of mice with collagen-induced arthritis treated with leflunomide.
    Dimitrova P; Ivanovska N
    Res Microbiol; 2006; 157(6):525-30. PubMed ID: 16797932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis.
    Han Y; Rhew KY
    Arch Pharm Res; 2012 Nov; 35(11):2021-7. PubMed ID: 23212645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulation by a low-virulence, agerminative variant of Candida albicans. Further evidence for macrophage activation as one of the effector mechanisms of nonspecific anti-infectious protection.
    Bistoni F; Verducci G; Perito S; Vecchiarelli A; Puccetti P; Marconi P; Cassone A
    J Med Vet Mycol; 1988; 26(5):285-99. PubMed ID: 2853217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic immunosuppression following a single pharyngeal aspiration of 1,2:5,6-dibenzanthracene in female B6C3F1 mice.
    Smith DC; Smith MJ; White KL
    J Immunotoxicol; 2010; 7(3):219-31. PubMed ID: 20509767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased tissue resistance in the nude mouse against Candida albicans without altering strain-dependent differences in susceptibility.
    Fulurija A; Ashman RB; Papadimitriou JM
    J Med Vet Mycol; 1997; 35(3):197-203. PubMed ID: 9229336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.
    Badger AM; Handler JA; Genell CA; Herzyk D; Gore E; Polsky R; Webb L; Bugelski PJ
    Int J Immunopharmacol; 1999 Mar; 21(3):161-76. PubMed ID: 10348366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-23 supports host defense against systemic Candida albicans infection by ensuring myeloid cell survival.
    Nur S; Sparber F; Lemberg C; Guiducci E; Schweizer TA; Zwicky P; Becher B; LeibundGut-Landmann S
    PLoS Pathog; 2019 Dec; 15(12):e1008115. PubMed ID: 31887131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with oxoglaucine can enhance host resistance to Candida albicans infection of mice with adjuvant arthritis.
    Ivanovska N; Hristova M
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):17-20. PubMed ID: 11025179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of infection- and defense-related genes via a dynamic host-pathogen interaction network using a Candida albicans-zebrafish infection model.
    Kuo ZY; Chuang YJ; Chao CC; Liu FC; Lan CY; Chen BS
    J Innate Immun; 2013; 5(2):137-52. PubMed ID: 23406717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The novel immunostimulant N-563, an analogue of deoxyspergualin, promotes resistance to Candida albicans infection in mice.
    Aoyagi K; Abe F; Nemoto K; Abe S; Ishizuka M; Takeuchi T; Yamaguchi H
    J Antibiot (Tokyo); 1994 Oct; 47(10):1077-83. PubMed ID: 7961155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modification of post-operative C. albicans sepsis by glucan immunostimulation.
    Browder IW; Williams DL; Kitahama A; Di Luzio NR
    Int J Immunopharmacol; 1984; 6(1):19-26. PubMed ID: 6724765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inoculation candidiasis in a murine model of severe combined immunodeficiency syndrome.
    Mahanty S; Greenfield RA; Joyce WA; Kincade PW
    Infect Immun; 1988 Dec; 56(12):3162-6. PubMed ID: 3182076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model.
    MacCallum DM
    FEMS Yeast Res; 2009 Oct; 9(7):1111-22. PubMed ID: 19845042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune-modulatory drugs alter Candida albicans-induced sleep patterns in rabbits.
    Toth LA
    Pharmacol Biochem Behav; 1995 Aug; 51(4):877-84. PubMed ID: 7675872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of muramyl dipeptide on renal candidiasis in genetically distinct mice.
    Marquis GA; Boushira M; Russo P; Montplaisir S
    APMIS; 1992 Nov; 100(11):967-75. PubMed ID: 1472365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adherence of Candida albicans to tissues from mice with drug- or radiation-induced immunodeficiencies.
    Brawner DL; Mori M
    J Infect Dis; 1992 Sep; 166(3):587-97. PubMed ID: 1500741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.